Bristol-Myers' Eliquis gets new FDA nod for use after ortho surgery | PharmaBoardroom

Bristol-Myers' Eliquis gets new FDA nod for use after ortho surgery

face
TAGS: ,

When Bristol-Myers Squibb and Pfizer launched their new anticoagulant, Eliquis, early last year, Wall Street analysts predicted it would be a $3-billion-a-year blockbuster. After more than a year of struggling to reach that goal, the companies got some good news late Friday, when the FDA approved the drug to reduce the risk of blood clots in the legs and lungs following hip or knee replacement surgery.

Latest Report